x连锁低磷血症佝偻病患者骨科治疗的并发症

Carl Gustaf Paludan, Kristoffer Koed Vittrup Thomsen, O. Rahbek, S. Kold
{"title":"x连锁低磷血症佝偻病患者骨科治疗的并发症","authors":"Carl Gustaf Paludan, Kristoffer Koed Vittrup Thomsen, O. Rahbek, S. Kold","doi":"10.1515/jpem-2021-0775","DOIUrl":null,"url":null,"abstract":"Abstract Objectives XLHR in children with a Rickets Severity Score ≥2 can now be treated with the new antibody drug, Burosumab, which prevents bone deformities and increases gait endurance. This study illustrates the extent of complications in the traditional orthopedic treatment of XLHR. The impact of surgery and severity of complications in this patient population has not been systematically assessed before. Methods The search strategy resulted in 215 studies and data were collected from 19 eligible studies and complications were categorized. Four medical charts of patients with XLHR at Aalborg University Hospital were assessed. Results One complication occurred on average per surgical procedure for XLHR in the published literature. The 168 reported complications were categorized as follows: Type I (n=79): Complications with minimal intervention required and treatment goal still achieved, Type II (n=41): Complications with substantial change in treatment plan and treatment goal still achieved, Type IIIA (n=23): Complications with failure to achieve treatment goal and no new pathology or permanent sequelae, Type IIIB (n=25): Complications with failure to achieve treatment goal and/or new pathology or permanent sequelae. Conclusions In average, one complication occurred per surgery and the severity of complications were substantial. The treatment goal was not achieved in 28% of surgeries whereof half of them resulted in permanent sequalae or new pathology. Our findings support the use of Burosumab for treatment of the skeletal changes in XLHR as the reported side-effects in Burosumab treatment appear negligible compared to the impact of surgeries and related complications (Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 2019;393:2416–27). However, orthopedic surgery might still be needed for correcting deformities restricting activities of daily living in XLHR patients.","PeriodicalId":16746,"journal":{"name":"Journal of Pediatric Endocrinology and Metabolism","volume":"97 1","pages":"1003 - 1009"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Complications of orthopedic treatment in patients diagnosed with X-linked hypophosphatemic rickets\",\"authors\":\"Carl Gustaf Paludan, Kristoffer Koed Vittrup Thomsen, O. Rahbek, S. Kold\",\"doi\":\"10.1515/jpem-2021-0775\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Objectives XLHR in children with a Rickets Severity Score ≥2 can now be treated with the new antibody drug, Burosumab, which prevents bone deformities and increases gait endurance. This study illustrates the extent of complications in the traditional orthopedic treatment of XLHR. The impact of surgery and severity of complications in this patient population has not been systematically assessed before. Methods The search strategy resulted in 215 studies and data were collected from 19 eligible studies and complications were categorized. Four medical charts of patients with XLHR at Aalborg University Hospital were assessed. Results One complication occurred on average per surgical procedure for XLHR in the published literature. The 168 reported complications were categorized as follows: Type I (n=79): Complications with minimal intervention required and treatment goal still achieved, Type II (n=41): Complications with substantial change in treatment plan and treatment goal still achieved, Type IIIA (n=23): Complications with failure to achieve treatment goal and no new pathology or permanent sequelae, Type IIIB (n=25): Complications with failure to achieve treatment goal and/or new pathology or permanent sequelae. Conclusions In average, one complication occurred per surgery and the severity of complications were substantial. The treatment goal was not achieved in 28% of surgeries whereof half of them resulted in permanent sequalae or new pathology. Our findings support the use of Burosumab for treatment of the skeletal changes in XLHR as the reported side-effects in Burosumab treatment appear negligible compared to the impact of surgeries and related complications (Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 2019;393:2416–27). However, orthopedic surgery might still be needed for correcting deformities restricting activities of daily living in XLHR patients.\",\"PeriodicalId\":16746,\"journal\":{\"name\":\"Journal of Pediatric Endocrinology and Metabolism\",\"volume\":\"97 1\",\"pages\":\"1003 - 1009\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatric Endocrinology and Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/jpem-2021-0775\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Endocrinology and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/jpem-2021-0775","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

佝偻病严重程度评分≥2的儿童XLHR现在可以用新的抗体药物burrosumab治疗,该药物可以预防骨畸形并增加步态耐力。本研究说明了XLHR传统矫形治疗中并发症的程度。手术的影响和并发症的严重程度在这一患者群体中还没有系统的评估。方法检索215项研究,收集19项符合条件的研究资料,并对并发症进行分类。对奥尔堡大学医院XLHR患者的四份病历进行了评估。结果在已发表的文献中,XLHR平均每次手术发生1例并发症。168例报告的并发症分为:I型(n=79):需要最小干预且仍达到治疗目标的并发症,II型(n=41):治疗方案发生重大变化且仍达到治疗目标的并发症,IIIA型(n=23):未能达到治疗目标且无新病理或永久性后遗症的并发症,IIIB型(n=25):未能达到治疗目标和/或新病理或永久性后遗症的并发症。结论平均每例手术发生1例并发症,并发症严重程度高。28%的手术未能达到治疗目标,其中一半的手术导致永久性后遗症或新的病理。我们的研究结果支持使用布若单抗治疗XLHR的骨骼变化,因为与手术和相关并发症的影响相比,布若单抗治疗的副作用似乎可以忽略不计(Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O,等)。布若单抗与常规治疗相比治疗x连锁低磷血症儿童:一项随机、主动对照、开放标签的3期试验《柳叶刀》2019年;393:2416-27)。然而,对于限制XLHR患者日常生活活动的畸形,可能仍然需要矫形手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Complications of orthopedic treatment in patients diagnosed with X-linked hypophosphatemic rickets
Abstract Objectives XLHR in children with a Rickets Severity Score ≥2 can now be treated with the new antibody drug, Burosumab, which prevents bone deformities and increases gait endurance. This study illustrates the extent of complications in the traditional orthopedic treatment of XLHR. The impact of surgery and severity of complications in this patient population has not been systematically assessed before. Methods The search strategy resulted in 215 studies and data were collected from 19 eligible studies and complications were categorized. Four medical charts of patients with XLHR at Aalborg University Hospital were assessed. Results One complication occurred on average per surgical procedure for XLHR in the published literature. The 168 reported complications were categorized as follows: Type I (n=79): Complications with minimal intervention required and treatment goal still achieved, Type II (n=41): Complications with substantial change in treatment plan and treatment goal still achieved, Type IIIA (n=23): Complications with failure to achieve treatment goal and no new pathology or permanent sequelae, Type IIIB (n=25): Complications with failure to achieve treatment goal and/or new pathology or permanent sequelae. Conclusions In average, one complication occurred per surgery and the severity of complications were substantial. The treatment goal was not achieved in 28% of surgeries whereof half of them resulted in permanent sequalae or new pathology. Our findings support the use of Burosumab for treatment of the skeletal changes in XLHR as the reported side-effects in Burosumab treatment appear negligible compared to the impact of surgeries and related complications (Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 2019;393:2416–27). However, orthopedic surgery might still be needed for correcting deformities restricting activities of daily living in XLHR patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信